

Press Release

Vetbiobank obtains Good Manufacturing Practices (GMP) certification for its veterinary cell therapy drugs and is awarded French government funding for its future biomanufacturing plant

- - Vetbiobank is the first French veterinary pharmaceutical company to obtain GMP (Good Manufacturing Practices) certification for cell biotherapy drugs.
- - Within the "France Relance" frameworks, SmartCellFactory, the company's industrial project in regenerative medicine, has just been awarded a governmental grant.
- - Vetbiobank accelerates its Series A financing for its last clinical phase before Marketing Authorization (MA)

Lyon, May 26, 2021

Vetbiobank, a specialist in animal biotherapies, becomes the first veterinary pharmaceutical company in France to receive GMP certification for its pharmaceutical manufacturing activities. Vetbiobank has thus reached a new milestone towards obtaining the first MA for its veterinary drug based on canine neonatal stem cells against osteoarthritis in dogs. Vetbiobank becomes one of the first laboratory to obtain this certification for a patented 3D bioproduction process, in a bioreactor, capable of efficiently meeting the needs of these mass markets.

Once this step has been achieved, Vetbiobank will now be able to initiate its final efficacy study (equivalent to phase 3 in human medicine) with products manufactured according to the certified industrial process, which can then be deployed on a large scale to progressively adapt to the demand in Europe. This increase in production capacity will be carried out within the framework of the "SmartCellFactory" modular and intelligent biomanufacturing infrastructure project, financially supported by the "France Relance" governmental plan for the acceleration and relocation of the "biomanufacturing of innovative therapies".

To finalize the clinical development of its flagship product and complete the deployment of its product pipeline in other chronic inflammatory diseases, Vetbiobank is raising a Series A round of financing.

"Vetbiobank's dedicated team has achieved a significant milestone with the GMP certification and today we would like to thank the French government and the BPI for their confidence and support with a grant that will allow Vetbiobank to recruit the necessary skills for its clinical and bioprocess engineering developments. These additional resources consolidate the financing plan of our Series A and will allow us to accelerate the final steps before the market launch of our products", commented Stéphane Maddens, President of Vetbiobank

About SmartCellFactory

SmartCellFactory is a project to create an innovative, scalable and artificial intelligence monitored biomanufacturing infrastructure. It will provide an answer to the challenges of large-scale industrial

manufacturing of cell-based biotherapies, in a "One Health" approach. The company plans to create more than 20 direct qualified jobs within 2 years."

About Vetbiobank

Vetbiobank develops biomedicines based on neonatal stem cells to treat chronic inflammatory diseases from which a growing number of pets suffer (osteoarthritis, atopic dermatitis, stomatitis...). Vetbiobank's ambition is to make them first-line treatments, thanks to their efficacy, low compliance constraints, excellent tolerance, and affordable cost.

Compared to adult stem cells, Vetbiobank's neonatal stem cells have significant advantages. They have a standardized biological potential, intact and not altered by age. They have a higher capacity of amplification and therefore of industrialization, a better microbiological safety, and their collection respects the animal welfare.

Vetbiobank will eventually offer veterinarians these therapeutic innovations that are easy to implement, and that enhance their expertise. Soon, these treatments will relieve owners of compliance constraints linked to standard treatments and will allow to improve the quality of life of their pets in a sustainable way.

For more information: www.vetbiobank.com

Press contact:

Nadia Plantier

n.plantier@vetbiobank.com